ID   NCOA3_HUMAN             Reviewed;        1424 AA.
AC   Q9Y6Q9; A4LAZ5; Q0VF45; Q5JYD9; Q5JYE0; Q9BR49; Q9UPC9; Q9UPG4;
AC   Q9UPG7;
DT   19-SEP-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1999, sequence version 1.
DT   10-MAY-2017, entry version 188.
DE   RecName: Full=Nuclear receptor coactivator 3;
DE            Short=NCoA-3;
DE            EC=2.3.1.48;
DE   AltName: Full=ACTR;
DE   AltName: Full=Amplified in breast cancer 1 protein;
DE            Short=AIB-1;
DE   AltName: Full=CBP-interacting protein;
DE            Short=pCIP;
DE   AltName: Full=Class E basic helix-loop-helix protein 42;
DE            Short=bHLHe42;
DE   AltName: Full=Receptor-associated coactivator 3;
DE            Short=RAC-3;
DE   AltName: Full=Steroid receptor coactivator protein 3;
DE            Short=SRC-3;
DE   AltName: Full=Thyroid hormone receptor activator molecule 1;
DE            Short=TRAM-1;
GN   Name=NCOA3; Synonyms=AIB1, BHLHE42, RAC3, TRAM1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND INTERACTION WITH
RP   CREBBP; PCAF; RARA; RXRA; THRA AND ESR.
RC   TISSUE=Pituitary;
RX   PubMed=9346901; DOI=10.1074/jbc.272.44.27629;
RA   Takeshita A., Cardona G.R., Koibuchi N., Suen C.-S., Chin W.W.;
RT   "TRAM-1, a novel 160-kDa thyroid hormone receptor activator molecule,
RT   exhibits distinct properties from steroid receptor coactivator-1.";
RL   J. Biol. Chem. 272:27629-27634(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3 AND 4), ENZYME ACTIVITY, AND
RP   VARIANT 1248-GLN--GLN-1250 DEL.
RC   TISSUE=Leukemia;
RX   PubMed=9267036; DOI=10.1016/S0092-8674(00)80516-4;
RA   Chen H., Lin R.J., Schiltz R.L., Chakravarti D., Nash A., Nagy L.,
RA   Privalsky M.L., Nakatani Y., Evans R.M.;
RT   "Nuclear receptor coactivator ACTR is a novel histone
RT   acetyltransferase and forms a multimeric activation complex with P/CAF
RT   and CBP/p300.";
RL   Cell 90:569-580(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5), AND INTERACTION WITH ESR.
RC   TISSUE=Lung;
RX   PubMed=9252329; DOI=10.1126/science.277.5328.965;
RA   Anzick S.L., Kononen J., Walker R.L., Azorsa D.O., Tanner M.M.,
RA   Guan X.-Y., Sauter G., Kallioniemi O.-P., Trent J.M., Meltzer P.S.;
RT   "AIB1, a steroid receptor coactivator amplified in breast and ovarian
RT   cancer.";
RL   Science 277:965-968(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5), INTERACTION WITH VDR; RARA;
RP   PPARA; RXRA; THRA AND ESR, AND VARIANT 1248-GLN--GLN-1250 DEL.
RC   TISSUE=Brain;
RX   PubMed=9238002; DOI=10.1073/pnas.94.16.8479;
RA   Li H., Gomes P.J., Chen J.D.;
RT   "RAC3, a steroid/nuclear receptor-associated coactivator that is
RT   related to SRC-1 and TIF2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:8479-8484(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS CYS-218; ILE-220;
RP   VAL-556; SER-559; HIS-586; ALA-777; LEU-1247 AND LYS-1247.
RG   NIEHS SNPs program;
RL   Submitted (MAR-2007) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
RA   Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
RA   Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
RA   Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R.,
RA   Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
RA   Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,
RA   Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S.,
RA   Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
RA   Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA   Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
RA   Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,
RA   Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
RA   Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   POLYMORPHISM OF POLY-GLN REGION.
RX   PubMed=9727751;
RA   Shirazi S.K., Bober M.A., Coetzee G.A.;
RT   "Polymorphic exonic CAG microsatellites in the gene amplified in
RT   breast cancer (AIB1 gene).";
RL   Clin. Genet. 54:102-103(1998).
RN   [10]
RP   ACETYLATION AT LYS-616; LYS-619 AND LYS-620 BY CREBBP, AND MUTAGENESIS
RP   OF LYS-616; 619-LYS-LYS-620; LYS-647; LYS-681; LYS-687; LYS-700 AND
RP   LYS-708.
RX   PubMed=10490106; DOI=10.1016/S0092-8674(00)80054-9;
RA   Chen H., Lin R.J., Xie W., Wilpitz D., Evans R.M.;
RT   "Regulation of hormone-induced histone hyperacetylation and gene
RT   activation via acetylation of an acetylase.";
RL   Cell 98:675-686(1999).
RN   [11]
RP   INTERACTION WITH NFKB1.
RX   PubMed=11094166; DOI=10.1016/S0014-5793(00)02223-7;
RA   Werbajh S., Nojek I., Lanz R., Costas M.A.;
RT   "RAC-3 is a NF-kappa B coactivator.";
RL   FEBS Lett. 485:195-199(2000).
RN   [12]
RP   INTERACTION WITH DDX5.
RX   PubMed=11250900; DOI=10.1093/emboj/20.6.1341;
RA   Watanabe M., Yanagisawa J., Kitagawa H., Takeyama K., Ogawa S.,
RA   Arao Y., Suzawa M., Kobayashi Y., Yano T., Yoshikawa H., Masuhiro Y.,
RA   Kato S.;
RT   "A subfamily of RNA-binding DEAD-box proteins acts as an estrogen
RT   receptor alpha coactivator through the N-terminal activation domain
RT   (AF-1) with an RNA coactivator, SRA.";
RL   EMBO J. 20:1341-1352(2001).
RN   [13]
RP   SUBUNIT OF A COMPLEX CONTAINING CREBBP; NCOA2; IKKA; IKKB AND IKBKG,
RP   AND PHOSPHORYLATION.
RX   PubMed=11971985; DOI=10.1128/MCB.22.10.3549-3561.2002;
RA   Wu R.-C., Qin J., Hashimoto Y., Wong J., Xu J., Tsai S.Y., Tsai M.-J.,
RA   O'Malley B.W.;
RT   "Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) coactivator
RT   activity by I kappa B kinase.";
RL   Mol. Cell. Biol. 22:3549-3561(2002).
RN   [14]
RP   INTERACTION WITH NR3C1.
RX   PubMed=12917342; DOI=10.1128/MCB.23.17.6210-6220.2003;
RA   Hsiao P.W., Fryer C.J., Trotter K.W., Wang W., Archer T.K.;
RT   "BAF60a mediates critical interactions between nuclear receptors and
RT   the BRG1 chromatin-remodeling complex for transactivation.";
RL   Mol. Cell. Biol. 23:6210-6220(2003).
RN   [15]
RP   INTERACTION WITH NPAS2.
RX   PubMed=14645221; DOI=10.1074/jbc.M311973200;
RA   Curtis A.M., Seo S.B., Westgate E.J., Rudic R.D., Smyth E.M.,
RA   Chakravarti D., FitzGerald G.A., McNamara P.;
RT   "Histone acetyltransferase-dependent chromatin remodeling and the
RT   vascular clock.";
RL   J. Biol. Chem. 279:7091-7097(2004).
RN   [16]
RP   INTERACTION WITH CASP8AP2.
RX   PubMed=15698540; DOI=10.1016/j.jsbmb.2004.09.003;
RA   Kino T., Ichijo T., Chrousos G.P.;
RT   "FLASH interacts with p160 coactivator subtypes and differentially
RT   suppresses transcriptional activity of steroid hormone receptors.";
RL   J. Steroid Biochem. Mol. Biol. 92:357-363(2004).
RN   [17]
RP   SUBUNIT.
RX   PubMed=16951154; DOI=10.1158/0008-5472.CAN-06-1636;
RA   Ma A.H., Xia L., Desai S.J., Boucher D.L., Guan Y., Shih H.M.,
RA   Shi X.B., deVere White R.W., Chen H.W., Tepper C.G., Kung H.J.;
RT   "Male germ cell-associated kinase, a male-specific kinase regulated by
RT   androgen, is a coactivator of androgen receptor in prostate cancer
RT   cells.";
RL   Cancer Res. 66:8439-8447(2006).
RN   [18]
RP   INTERACTION WITH PSMB9.
RX   PubMed=16957778; DOI=10.1038/sj.emboj.7601306;
RA   Zhang H., Sun L., Liang J., Yu W., Zhang Y., Wang Y., Chen Y., Li R.,
RA   Sun X., Shang Y.;
RT   "The catalytic subunit of the proteasome is engaged in the entire
RT   process of estrogen receptor-regulated transcription.";
RL   EMBO J. 25:4223-4233(2006).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-857 AND SER-867, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [20]
RP   INTERACTION WITH ATAD2.
RX   PubMed=17998543; DOI=10.1073/pnas.0705814104;
RA   Zou J.X., Revenko A.S., Li L.B., Gemo A.T., Chen H.-W.;
RT   "ANCCA, an estrogen-regulated AAA+ ATPase coactivator for ERalpha, is
RT   required for coregulator occupancy and chromatin modification.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:18067-18072(2007).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-214; SER-551; SER-728
RP   AND SER-857, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [23]
RP   PHOSPHORYLATION AT SER-601 BY CSNK1D/CK1, AND INTERACTION WITH CSNK1D.
RX   PubMed=19339517; DOI=10.1093/nar/gkp136;
RA   Giamas G., Castellano L., Feng Q., Knippschild U., Jacob J.,
RA   Thomas R.S., Coombes R.C., Smith C.L., Jiao L.R., Stebbing J.;
RT   "CK1delta modulates the transcriptional activity of ERalpha via AIB1
RT   in an estrogen-dependent manner and regulates ERalpha-AIB1
RT   interactions.";
RL   Nucleic Acids Res. 37:3110-3123(2009).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-857, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [25]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-687, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-214; SER-857 AND
RP   SER-867, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [28]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-214; SER-551; SER-694;
RP   SER-728; SER-857; SER-1033 AND SER-1330, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-551, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [31]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-1171; ARG-1177 AND ARG-1188,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.O113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V.,
RA   Aguiar M., Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C.,
RA   Vemulapalli V., Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
CC   -!- FUNCTION: Nuclear receptor coactivator that directly binds nuclear
CC       receptors and stimulates the transcriptional activities in a
CC       hormone-dependent fashion. Plays a central role in creating a
CC       multisubunit coactivator complex, which probably acts via
CC       remodeling of chromatin. Involved in the coactivation of different
CC       nuclear receptors, such as for steroids (GR and ER), retinoids
CC       (RARs and RXRs), thyroid hormone (TRs), vitamin D3 (VDR) and
CC       prostanoids (PPARs). Displays histone acetyltransferase activity.
CC       Also involved in the coactivation of the NF-kappa-B pathway via
CC       its interaction with the NFKB1 subunit.
CC   -!- CATALYTIC ACTIVITY: Acetyl-CoA + [protein]-L-lysine = CoA +
CC       [protein]-N(6)-acetyl-L-lysine. {ECO:0000269|PubMed:9267036}.
CC   -!- ENZYME REGULATION: Coactivator activity on nuclear receptors and
CC       NF-kappa-B pathways is enhanced by various hormones, and the TNF
CC       cytokine, respectively. TNF stimulation probably enhances
CC       phosphorylation, which in turn activates coactivator function. In
CC       contrast, acetylation by CREBBP apparently suppresses coactivation
CC       of target genes by disrupting its association with nuclear
CC       receptors. Binds to CSNK1D.
CC   -!- SUBUNIT: Interacts with CARM1 (By similarity). Present in a
CC       complex containing NCOA2, IKKA, IKKB, IKBKG and the histone
CC       acetyltransferase protein CREBBP. Interacts with CASP8AP2, NR3C1
CC       and PCAF. Interacts with ATAD2 and this interaction is enhanced by
CC       estradiol. Found in a complex containing NCOA3, AR and MAK.
CC       Interacts with DDX5. Interacts with PSMB9. Interacts with NPAS2.
CC       Interacts with NR4A3 (By similarity). {ECO:0000250,
CC       ECO:0000250|UniProtKB:O09000, ECO:0000269|PubMed:11094166,
CC       ECO:0000269|PubMed:11250900, ECO:0000269|PubMed:11971985,
CC       ECO:0000269|PubMed:12917342, ECO:0000269|PubMed:14645221,
CC       ECO:0000269|PubMed:15698540, ECO:0000269|PubMed:16951154,
CC       ECO:0000269|PubMed:16957778, ECO:0000269|PubMed:17998543,
CC       ECO:0000269|PubMed:19339517, ECO:0000269|PubMed:9238002,
CC       ECO:0000269|PubMed:9252329, ECO:0000269|PubMed:9346901}.
CC   -!- INTERACTION:
CC       Q86X55:CARM1; NbExp=12; IntAct=EBI-81196, EBI-2339854;
CC       Q92841:DDX17; NbExp=2; IntAct=EBI-81196, EBI-746012;
CC       Q09472:EP300; NbExp=2; IntAct=EBI-81196, EBI-447295;
CC       P03372:ESR1; NbExp=4; IntAct=EBI-81196, EBI-78473;
CC       O14920:IKBKB; NbExp=3; IntAct=EBI-81196, EBI-81266;
CC       P28065:PSMB9; NbExp=3; IntAct=EBI-81196, EBI-603300;
CC       P61289:PSME3; NbExp=5; IntAct=EBI-81196, EBI-355546;
CC       P60484:PTEN; NbExp=2; IntAct=EBI-81196, EBI-696162;
CC       P10276:RARA; NbExp=2; IntAct=EBI-81196, EBI-413374;
CC       O43791:SPOP; NbExp=6; IntAct=EBI-81196, EBI-743549;
CC       P48281:Vdr (xeno); NbExp=2; IntAct=EBI-81196, EBI-346797;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Mainly cytoplasmic
CC       and weakly nuclear. Upon TNF activation and subsequent
CC       phosphorylation, it translocates from the cytoplasm to the
CC       nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=1;
CC         IsoId=Q9Y6Q9-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9Y6Q9-2; Sequence=VSP_003407;
CC       Name=3;
CC         IsoId=Q9Y6Q9-3; Sequence=VSP_003405, VSP_003407, VSP_003408;
CC       Name=4;
CC         IsoId=Q9Y6Q9-4; Sequence=VSP_003405, VSP_003406, VSP_003407,
CC                                  VSP_003408;
CC       Name=5;
CC         IsoId=Q9Y6Q9-5; Sequence=VSP_003408;
CC   -!- TISSUE SPECIFICITY: Widely expressed. High expression in heart,
CC       skeletal muscle, pancreas and placenta. Low expression in brain,
CC       and very low in lung, liver and kidney.
CC   -!- DOMAIN: Contains three Leu-Xaa-Xaa-Leu-Leu (LXXLL) motifs. Motifs
CC       1 and 2 are essential for the association with nuclear receptors,
CC       and constitute the RID domain (Receptor-interacting domain).
CC   -!- PTM: Acetylated by CREBBP. Acetylation occurs in the RID domain,
CC       and disrupts the interaction with nuclear receptors and regulates
CC       its function. {ECO:0000269|PubMed:10490106}.
CC   -!- PTM: Methylated by CARM1. {ECO:0000250}.
CC   -!- PTM: Phosphorylated by IKK complex. Regulated its function.
CC       Phosphorylation at Ser-601 by CK1 promotes coactivator function.
CC       {ECO:0000269|PubMed:11971985, ECO:0000269|PubMed:19339517}.
CC   -!- POLYMORPHISM: The length of the poly-Gln region is polymorphic in
CC       the normal population. {ECO:0000269|PubMed:9727751}.
CC   -!- MISCELLANEOUS: NCOA3 is frequently amplified or overexpressed in
CC       breast and ovarian cancers.
CC   -!- SIMILARITY: Belongs to the SRC/p160 nuclear receptor coactivator
CC       family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/NCOA3ID505ch20q13.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/ncoa3/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF016031; AAC51849.1; -; mRNA.
DR   EMBL; AF036892; AAB92368.1; -; mRNA.
DR   EMBL; AF012108; AAC51677.1; -; mRNA.
DR   EMBL; AF010227; AAC51663.1; -; mRNA.
DR   EMBL; EF488684; ABO43042.1; -; Genomic_DNA.
DR   EMBL; AL034418; CAB40662.1; -; Genomic_DNA.
DR   EMBL; AL034418; CAC17693.1; -; Genomic_DNA.
DR   EMBL; AL034418; CAI42141.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75698.1; -; Genomic_DNA.
DR   EMBL; CH471077; EAW75702.1; -; Genomic_DNA.
DR   EMBL; BC119001; AAI19002.1; -; mRNA.
DR   CCDS; CCDS13406.1; -. [Q9Y6Q9-5]
DR   CCDS; CCDS13407.1; -. [Q9Y6Q9-1]
DR   CCDS; CCDS54472.1; -. [Q9Y6Q9-3]
DR   PIR; T03851; T03851.
DR   RefSeq; NP_001167559.1; NM_001174088.1. [Q9Y6Q9-3]
DR   RefSeq; NP_006525.2; NM_006534.3. [Q9Y6Q9-5]
DR   RefSeq; NP_858045.1; NM_181659.2. [Q9Y6Q9-1]
DR   UniGene; Hs.592142; -.
DR   PDB; 1KBH; NMR; -; A=1045-1091.
DR   PDB; 3L3X; X-ray; 1.55 A; B=618-629.
DR   PDB; 3L3Z; X-ray; 2.00 A; B=735-746.
DR   PDBsum; 1KBH; -.
DR   PDBsum; 3L3X; -.
DR   PDBsum; 3L3Z; -.
DR   DisProt; DP00343; -.
DR   ProteinModelPortal; Q9Y6Q9; -.
DR   SMR; Q9Y6Q9; -.
DR   BioGrid; 113841; 109.
DR   DIP; DIP-30876N; -.
DR   IntAct; Q9Y6Q9; 50.
DR   MINT; MINT-231818; -.
DR   STRING; 9606.ENSP00000361066; -.
DR   BindingDB; Q9Y6Q9; -.
DR   ChEMBL; CHEMBL1615382; -.
DR   iPTMnet; Q9Y6Q9; -.
DR   PhosphoSitePlus; Q9Y6Q9; -.
DR   SwissPalm; Q9Y6Q9; -.
DR   BioMuta; NCOA3; -.
DR   DMDM; 23396777; -.
DR   EPD; Q9Y6Q9; -.
DR   PaxDb; Q9Y6Q9; -.
DR   PeptideAtlas; Q9Y6Q9; -.
DR   PRIDE; Q9Y6Q9; -.
DR   Ensembl; ENST00000371997; ENSP00000361065; ENSG00000124151. [Q9Y6Q9-3]
DR   Ensembl; ENST00000371998; ENSP00000361066; ENSG00000124151. [Q9Y6Q9-1]
DR   Ensembl; ENST00000372004; ENSP00000361073; ENSG00000124151. [Q9Y6Q9-5]
DR   GeneID; 8202; -.
DR   KEGG; hsa:8202; -.
DR   UCSC; uc002xtk.4; human. [Q9Y6Q9-1]
DR   CTD; 8202; -.
DR   DisGeNET; 8202; -.
DR   GeneCards; NCOA3; -.
DR   HGNC; HGNC:7670; NCOA3.
DR   HPA; CAB009800; -.
DR   HPA; HPA024210; -.
DR   MIM; 601937; gene.
DR   neXtProt; NX_Q9Y6Q9; -.
DR   OpenTargets; ENSG00000124151; -.
DR   PharmGKB; PA31472; -.
DR   eggNOG; ENOG410IQ5R; Eukaryota.
DR   eggNOG; ENOG410ZDZC; LUCA.
DR   GeneTree; ENSGT00530000063109; -.
DR   HOVERGEN; HBG052583; -.
DR   InParanoid; Q9Y6Q9; -.
DR   KO; K11256; -.
DR   OMA; PMSGMPM; -.
DR   OrthoDB; EOG091G152H; -.
DR   PhylomeDB; Q9Y6Q9; -.
DR   TreeFam; TF332652; -.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.
DR   Reactome; R-HSA-5617472; Activation of anterior HOX genes in hindbrain development during early embryogenesis.
DR   Reactome; R-HSA-5687128; MAPK6/MAPK4 signaling.
DR   SignaLink; Q9Y6Q9; -.
DR   SIGNOR; Q9Y6Q9; -.
DR   ChiTaRS; NCOA3; human.
DR   EvolutionaryTrace; Q9Y6Q9; -.
DR   GeneWiki; Nuclear_receptor_coactivator_3; -.
DR   GenomeRNAi; 8202; -.
DR   PRO; PR:Q9Y6Q9; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   Bgee; ENSG00000124151; -.
DR   CleanEx; HS_NCOA3; -.
DR   CleanEx; HS_RAC3; -.
DR   CleanEx; HS_TRAM1; -.
DR   Genevisible; Q9Y6Q9; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0000790; C:nuclear chromatin; IDA:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0043234; C:protein complex; IMP:CAFA.
DR   GO; GO:0050681; F:androgen receptor binding; NAS:UniProtKB.
DR   GO; GO:0097718; F:disordered domain specific binding; IPI:CAFA.
DR   GO; GO:0004402; F:histone acetyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0016922; F:ligand-dependent nuclear receptor binding; IPI:UniProtKB.
DR   GO; GO:0030374; F:ligand-dependent nuclear receptor transcription coactivator activity; IBA:GO_Central.
DR   GO; GO:0035257; F:nuclear hormone receptor binding; IDA:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IMP:CAFA.
DR   GO; GO:0047485; F:protein N-terminus binding; IPI:UniProtKB.
DR   GO; GO:0046966; F:thyroid hormone receptor binding; NAS:UniProtKB.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB.
DR   GO; GO:0030521; P:androgen receptor signaling pathway; NAS:UniProtKB.
DR   GO; GO:0071392; P:cellular response to estradiol stimulus; IDA:BHF-UCL.
DR   GO; GO:0032870; P:cellular response to hormone stimulus; IBA:GO_Central.
DR   GO; GO:0030522; P:intracellular receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0045618; P:positive regulation of keratinocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; NAS:UniProtKB.
DR   GO; GO:0035624; P:receptor transactivation; TAS:UniProtKB.
DR   GO; GO:2001141; P:regulation of RNA biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   CDD; cd00083; HLH; 1.
DR   CDD; cd00130; PAS; 1.
DR   Gene3D; 1.10.287.1070; -; 1.
DR   Gene3D; 2.130.10.10; -; 1.
DR   Gene3D; 4.10.280.10; -; 1.
DR   InterPro; IPR011598; bHLH_dom.
DR   InterPro; IPR010011; DUF1518.
DR   InterPro; IPR032565; DUF4927.
DR   InterPro; IPR028818; NCOA3.
DR   InterPro; IPR009110; Nuc_rcpt_coact.
DR   InterPro; IPR014920; Nuc_rcpt_coact_Ncoa-typ.
DR   InterPro; IPR017426; Nuclear_rcpt_coactivator.
DR   InterPro; IPR000014; PAS.
DR   InterPro; IPR013767; PAS_fold.
DR   InterPro; IPR014935; SRC/p160_LXXLL.
DR   InterPro; IPR015943; WD40/YVTN_repeat-like_dom.
DR   PANTHER; PTHR10684; PTHR10684; 1.
DR   PANTHER; PTHR10684:SF6; PTHR10684:SF6; 1.
DR   Pfam; PF07469; DUF1518; 1.
DR   Pfam; PF16279; DUF4927; 1.
DR   Pfam; PF08815; Nuc_rec_co-act; 1.
DR   Pfam; PF00989; PAS; 1.
DR   Pfam; PF08832; SRC-1; 1.
DR   PIRSF; PIRSF038181; Nuclear_receptor_coactivator; 1.
DR   SMART; SM01151; DUF1518; 1.
DR   SMART; SM00353; HLH; 1.
DR   SMART; SM00091; PAS; 1.
DR   SUPFAM; SSF47459; SSF47459; 1.
DR   SUPFAM; SSF55785; SSF55785; 2.
DR   SUPFAM; SSF69125; SSF69125; 1.
DR   PROSITE; PS50888; BHLH; 1.
DR   PROSITE; PS50112; PAS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Acyltransferase;
KW   Alternative splicing; Complete proteome; Cytoplasm; Methylation;
KW   Nucleus; Phosphoprotein; Polymorphism; Reference proteome; Repeat;
KW   Transcription; Transcription regulation; Transferase.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:22814378}.
FT   CHAIN         2   1424       Nuclear receptor coactivator 3.
FT                                /FTId=PRO_0000094406.
FT   DOMAIN       25     82       bHLH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00981}.
FT   DOMAIN      110    180       PAS. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00140}.
FT   REGION     1023   1093       Interaction with CREBBP.
FT                                {ECO:0000269|PubMed:9346901}.
FT   REGION     1097   1304       Acetyltransferase.
FT   MOTIF       685    689       LXXLL motif 1.
FT   MOTIF       738    742       LXXLL motif 2.
FT   MOTIF      1057   1061       LXXLL motif 3.
FT   COMPBIAS    505    671       Ser-rich.
FT   COMPBIAS    976    980       Poly-Gln.
FT   COMPBIAS   1248   1278       Poly-Gln.
FT   COMPBIAS   1392   1417       Met-rich.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000244|PubMed:22814378}.
FT   MOD_RES     214    214       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     551    551       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     569    569       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O09000}.
FT   MOD_RES     601    601       Phosphoserine; by CK1.
FT                                {ECO:0000269|PubMed:19339517}.
FT   MOD_RES     616    616       N6-acetyllysine; by CREBBP.
FT                                {ECO:0000269|PubMed:10490106}.
FT   MOD_RES     619    619       N6-acetyllysine; by CREBBP.
FT                                {ECO:0000269|PubMed:10490106}.
FT   MOD_RES     620    620       N6-acetyllysine; by CREBBP.
FT                                {ECO:0000269|PubMed:10490106}.
FT   MOD_RES     687    687       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     694    694       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     728    728       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     857    857       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     860    860       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O09000}.
FT   MOD_RES     867    867       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:20068231}.
FT   MOD_RES    1033   1033       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1171   1171       Asymmetric dimethylarginine.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES    1177   1177       Asymmetric dimethylarginine.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES    1188   1188       Asymmetric dimethylarginine.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES    1330   1330       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ     321    321       E -> EVTSDGIFSPT (in isoform 3 and
FT                                isoform 4). {ECO:0000303|PubMed:9267036}.
FT                                /FTId=VSP_003405.
FT   VAR_SEQ     837    901       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:9267036}.
FT                                /FTId=VSP_003406.
FT   VAR_SEQ     903    917       Missing (in isoform 2, isoform 3 and
FT                                isoform 4). {ECO:0000303|PubMed:9267036,
FT                                ECO:0000303|PubMed:9346901}.
FT                                /FTId=VSP_003407.
FT   VAR_SEQ    1214   1217       Missing (in isoform 3, isoform 4 and
FT                                isoform 5). {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:9238002,
FT                                ECO:0000303|PubMed:9252329,
FT                                ECO:0000303|PubMed:9267036}.
FT                                /FTId=VSP_003408.
FT   VARIANT     218    218       R -> C (in dbSNP:rs6094752).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_053527.
FT   VARIANT     220    220       R -> I (in dbSNP:rs72645252).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_060695.
FT   VARIANT     369    369       L -> F (in dbSNP:rs6094756).
FT                                /FTId=VAR_053528.
FT   VARIANT     460    460       G -> R (in dbSNP:rs1052765).
FT                                /FTId=VAR_013831.
FT   VARIANT     556    556       I -> V (in dbSNP:rs72645272).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_060696.
FT   VARIANT     559    559       P -> S (in dbSNP:rs2230781).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_013832.
FT   VARIANT     586    586       Q -> H (in dbSNP:rs2230782).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_013833.
FT   VARIANT     777    777       S -> A (in dbSNP:rs2230783).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_053529.
FT   VARIANT    1247   1247       M -> K (in dbSNP:rs72645299).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_060697.
FT   VARIANT    1247   1247       M -> L (in dbSNP:rs72645298).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_060698.
FT   VARIANT    1248   1250       Missing. {ECO:0000269|PubMed:9238002,
FT                                ECO:0000269|PubMed:9267036}.
FT                                /FTId=VAR_013834.
FT   MUTAGEN     616    616       K->Q: Strongly reduces acetylation by
FT                                CREBBP. {ECO:0000269|PubMed:10490106}.
FT   MUTAGEN     619    620       KK->QQ: Abolishes acetylation by CREBBP.
FT                                {ECO:0000269|PubMed:10490106}.
FT   MUTAGEN     647    647       K->Q: Does not affect acetylation by
FT                                CREBBP. {ECO:0000269|PubMed:10490106}.
FT   MUTAGEN     681    681       K->Q: Does not affect acetylation by
FT                                CREBBP. {ECO:0000269|PubMed:10490106}.
FT   MUTAGEN     687    687       K->Q: Does not affect acetylation by
FT                                CREBBP. {ECO:0000269|PubMed:10490106}.
FT   MUTAGEN     700    700       K->Q: Does not affect acetylation by
FT                                CREBBP. {ECO:0000269|PubMed:10490106}.
FT   MUTAGEN     708    708       K->Q: Does not affect acetylation by
FT                                CREBBP. {ECO:0000269|PubMed:10490106}.
FT   CONFLICT    131    132       DG -> EA (in Ref. 4; AAC51663).
FT                                {ECO:0000305}.
FT   HELIX       619    626       {ECO:0000244|PDB:3L3X}.
FT   HELIX       736    743       {ECO:0000244|PDB:3L3Z}.
FT   HELIX      1049   1060       {ECO:0000244|PDB:1KBH}.
FT   HELIX      1069   1075       {ECO:0000244|PDB:1KBH}.
FT   HELIX      1078   1084       {ECO:0000244|PDB:1KBH}.
FT   HELIX      1086   1088       {ECO:0000244|PDB:1KBH}.
SQ   SEQUENCE   1424 AA;  155293 MW;  732CDF0423161679 CRC64;
     MSGLGENLDP LASDSRKRKL PCDTPGQGLT CSGEKRRREQ ESKYIEELAE LISANLSDID
     NFNVKPDKCA ILKETVRQIR QIKEQGKTIS NDDDVQKADV SSTGQGVIDK DSLGPLLLQA
     LDGFLFVVNR DGNIVFVSEN VTQYLQYKQE DLVNTSVYNI LHEEDRKDFL KNLPKSTVNG
     VSWTNETQRQ KSHTFNCRML MKTPHDILED INASPEMRQR YETMQCFALS QPRAMMEEGE
     DLQSCMICVA RRITTGERTF PSNPESFITR HDLSGKVVNI DTNSLRSSMR PGFEDIIRRC
     IQRFFSLNDG QSWSQKRHYQ EAYLNGHAET PVYRFSLADG TIVTAQTKSK LFRNPVTNDR
     HGFVSTHFLQ REQNGYRPNP NPVGQGIRPP MAGCNSSVGG MSMSPNQGLQ MPSSRAYGLA
     DPSTTGQMSG ARYGGSSNIA SLTPGPGMQS PSSYQNNNYG LNMSSPPHGS PGLAPNQQNI
     MISPRNRGSP KIASHQFSPV AGVHSPMASS GNTGNHSFSS SSLSALQAIS EGVGTSLLST
     LSSPGPKLDN SPNMNITQPS KVSNQDSKSP LGFYCDQNPV ESSMCQSNSR DHLSDKESKE
     SSVEGAENQR GPLESKGHKK LLQLLTCSSD DRGHSSLTNS PLDSSCKESS VSVTSPSGVS
     SSTSGGVSST SNMHGSLLQE KHRILHKLLQ NGNSPAEVAK ITAEATGKDT SSITSCGDGN
     VVKQEQLSPK KKENNALLRY LLDRDDPSDA LSKELQPQVE GVDNKMSQCT SSTIPSSSQE
     KDPKIKTETS EEGSGDLDNL DAILGDLTSS DFYNNSISSN GSHLGTKQQV FQGTNSLGLK
     SSQSVQSIRP PYNRAVSLDS PVSVGSSPPV KNISAFPMLP KQPMLGGNPR MMDSQENYGS
     SMGGPNRNVT VTQTPSSGDW GLPNSKAGRM EPMNSNSMGR PGGDYNTSLP RPALGGSIPT
     LPLRSNSIPG ARPVLQQQQQ MLQMRPGEIP MGMGANPYGQ AAASNQLGSW PDGMLSMEQV
     SHGTQNRPLL RNSLDDLVGP PSNLEGQSDE RALLDQLHTL LSNTDATGLE EIDRALGIPE
     LVNQGQALEP KQDAFQGQEA AVMMDQKAGL YGQTYPAQGP PMQGGFHLQG QSPSFNSMMN
     QMNQQGNFPL QGMHPRANIM RPRTNTPKQL RMQLQQRLQG QQFLNQSRQA LELKMENPTA
     GGAAVMRPMM QPQVSSQQGF LNAQMVAQRS RELLSHHFRQ QRVAMMMQQQ QQQQQQQQQQ
     QQQQQQQQQQ QQQQQQTQAF SPPPNVTASP SMDGLLAGPT MPQAPPQQFP YQPNYGMGQQ
     PDPAFGRVSS PPNAMMSSRM GPSQNPMMQH PQAASIYQSS EMKGWPSGNL ARNSSFSQQQ
     FAHQGNPAVY SMVHMNGSSG HMGQMNMNPM PMSGMPMGPD QKYC
//
